Telavancin for Injection Articles

Clinigen and Theravance deal on Vibativ; Cubist expands rights to ceftolozane

12 March 2013

Mixed FDA panel vote for Theravance's Vibativ for nosocomial pneumonia

3 December 2012

Astellas pulls out of deal with Theravance

9 January 2012

Astellas get EU approval for Vibativ for nosocomial pneumonia caused by MRSA

15 September 2011

Majority of US surveyed MCOs will consider reimbursing novel OPAT agents; report

17 August 2011

Slew of good news from EMA advisory panel for Benlysta, Fampyra, Vibativ, Victrelis, Xgeva and Yervoy

23 May 2011

Generic erosion will constrain hospital-acquired infections drug market growth through 2019

14 December 2010

US FDA says Theravance/Astellas’ Vibativ NDA for NP is incomplete

29 January 2010

Health Canada clears Astellas/Theravance’s Vibativ for cSSSI indications

2 October 2009

US FDA approves Theravance and Astellas’ Vibativ

14 September 2009

CHMP gives nod to Vidaza and Lunivia, while Astellas withdraws telavancin MAA

3 November 2008

Showing 1-11 of 11 articles

Go to beginningPrevious
  • 1
NextGo to end